ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
말라리아 백신 시장의 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 34.1%로 201억 9,000만 달러로 성장할 전망입니다. 예측기간의 성장은 세계적인 말라리아 대처 목표, 접근 프로그램 확대, 백신 접종률 증가, 세계적인 백신 제휴, 기후 변화의 영향으로 인해 발생할 전망입니다. 예측기간의 주요 동향은 기술 혁신, 민간 및 정부 파트너십, 국제 협력, 백신 기술의 진보 등입니다.
향후 5년간의 예측 성장률 34.1%는 이 시장의 과거 예측에서 0.4% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 영국이나 스페인에서 수입되는 RTS, S/AS01(모스퀴릭스) 백신이나 어쥬번트 시스템의 비용을 상승시키고, 아웃브레이크 대처능력을 저하시키며, 공중위생 프로그램의 비용을 증가시킬 가능성이 있기 때문에 미국의 의료 활동을 혼란시킬 가능성이 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 예상됩니다.
말라리아 백신 시장은 모기와 관련된 질병 증가로 성장할 것으로 예측됩니다. 모기에 물려 감염되는 이러한 질병은 다양한 질병을 구성합니다. 말라리아 백신 시장의 주요 제품인 RTS, S/AS01(RTS, S) 백신은 기생충을 인식하고 싸우도록 면역계를 훈련하여 모기가 매개하는 감염의 영향을 예방하고 완화하는 데 사용됩니다. 세계보건기구(WHO)의 2023년 11월 보고에 따르면 2022년 세계에서 발생한 말라리아 환자는 추정 2억 4,900만 명으로 전년 대비 500만 명 증가했습니다. 파키스탄은 상당한 증가를 보고했으며, 2021년 50만 건에 비해 2022년 260만 건에 이르렀습니다. 모기와 관련된 질병의 발생이 증가하고 있다는 점은 말라리아 백신 시장 성장의 촉매가 되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 말라리아 백신 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 말라리아 백신 시장 : 성장률 분석
세계의 말라리아 백신 시장 실적 : 규모와 성장(2019-2024년)
세계의 말라리아 백신 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 말라리아 백신 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 말라리아 백신 시장 : 원충별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
열대열 말라리아 원충
3일열 말라리아 원충
하마다라카속
세계의 말라리아 백신 시장 : 백신 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
전적혈구
적혈구
다항원
기타 백신
세계의 말라리아 백신 시장 : 투여경로별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
근육내
피하
혈관
기타 루트
세계의 말라리아 백신 시장 : 유통채널별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
공공
민간
세계의 말라리아 백신 시장 : 세분화 열대열 말라리아 원충(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
RTS, S/AS01 백신
기타 실험 백신
세계의 말라리아 백신 시장 : 세분화 3일열 말라리아 원충(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
개발 중인 후보 백신
혼합 백신
세계의 말라리아 백신 시장 : 세분화 하마다라카속(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
감염 전파 저지 백신
벡터 제어 접근법
제7장 지역별/국가별 분석
세계의 말라리아 백신 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 말라리아 백신 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
말라리아 백신 시장 : 경쟁 구도
말라리아 백신 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Ipca Laboratories Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline Plc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Takeda Pharmaceutical Co Ltd.
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC.
Lupin
Taj Pharmaceuticals Limited.
Nobelpharma Co. Ltd.
Bliss GVS Pharma Ltd.
Sanaria Inc.
Precigen Inc.
AdvaCare Pharma
CellFree Sciences
Actiza Pharmaceutical Private Limited
Sumaya Biotech
VLP Therapeutics LLC
GeoVax Labs Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
말라리아 백신 시장(2029년) : 새로운 기회를 제공하는 국가
말라리아 백신 시장(2029년) : 새로운 기회를 제공하는 부문
말라리아 백신 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Malaria vaccines are specialized vaccines developed to prevent malaria, a potentially life-threatening infectious disease transmitted through mosquito bites and caused by parasites belonging to the Plasmodium genus. The primary objective of these vaccines is to confer immunity against the Plasmodium parasites, offering protection against the development of malaria.
The primary types of agents involved in malaria vaccines are Plasmodium falciparum, Plasmodium vivax, and Anopheles species. Plasmodium falciparum is a protozoan parasite accountable for the most severe and deadly form of malaria in humans. Various types of malaria vaccines include pre-erythrocytic, erythrocytic, multi-antigen, and others, and they can be administered through different routes such as intramuscular, subcutaneous, intradermal, among others. The distribution of these vaccines is facilitated through various channels, including both public and private avenues.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The malaria vaccines market research report is one of a series of new reports from The Business Research Company that provides malaria vaccines market statistics, including malaria vaccines industry global market size, regional shares, competitors with a malaria vaccines market share, detailed malaria vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the malaria vaccines industry. This malaria vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The malaria vaccines market size has grown exponentially in recent years. It will grow from $4.7 billion in 2024 to $6.24 billion in 2025 at a compound annual growth rate (CAGR) of 32.7%. The growth in the historic period can be attributed to high malaria burden, global health initiatives, funding and grants, malaria control programs, government support and regulatory frameworks.
The malaria vaccines market size is expected to see exponential growth in the next few years. It will grow to $20.19 billion in 2029 at a compound annual growth rate (CAGR) of 34.1%. The growth in the forecast period can be attributed to global elimination goals, expanded access programs, increasing vaccine coverage, global vaccine alliances, climate change impact. Major trends in the forecast period include technological innovations, public-private partnerships, international collaboration, advancements in vaccine technology, advancements in vaccine technology.
The forecast of 34.1% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. global health initiatives by increasing costs for RTS,S/AS01 (Mosquirix) vaccines and adjuvant systems imported from the UK and Spain, potentially undermining outbreak preparedness and raising public health program expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The malaria vaccine market is anticipated to witness growth owing to an increase in mosquito-related diseases. These diseases, transmitted through mosquito bites, constitute a diverse range of illnesses. The RTS, S/AS01 (RTS, S) vaccine, a prominent player in the malaria vaccine market, is employed to prevent and mitigate the impact of mosquito-borne infectious diseases by training the immune system to recognize and combat the parasite. According to a November 2023 report from the World Health Organization (WHO), an estimated 249 million malaria cases occurred globally in 2022, reflecting a rise of 5 million cases from the previous year. Pakistan reported a significant increase, reaching an estimated 2.6 million cases in 2022 compared to 500,000 cases in 2021. The escalating incidence of mosquito-related diseases serves as a catalyst for the malaria vaccine market's growth.
Leading companies in the malaria vaccine market are actively innovating by developing products tailored for specific demographics, such as vaccines designed for children's malaria. This strategic approach aims to capture larger customer bases, boost sales, and augment revenue streams. Vaccines targeting mosquito-borne diseases are specialized immunological formulations offering protection against illnesses transmitted by mosquitoes. An exemplar in this category is a pediatric vaccine combating Plasmodium falciparum, the deadliest malaria parasite globally, and prevalent in Africa. In November 2022, Malawi and the World Health Organization (WHO) introduced Africa's inaugural children's malaria vaccine. The RTSS vaccine, tailored for young children, exhibits the potential to reduce mortality from the mosquito-borne disease. Despite a modest effectiveness rate of 30%, the vaccine, after pilot testing on over one million children in Ghana, Kenya, and Malawi, instills optimism for saving lives among the 400,000 individuals succumbing to malaria annually.
In August 2022, GlaxoSmithKline Plc, a prominent UK-based biopharmaceutical company, completed the acquisition of Affinivax Inc. for $3.3 billion. This strategic acquisition positions GlaxoSmithKline (GSK) to strengthen its pipeline of novel vaccines and enhance its presence in the Boston area, leveraging Affinivax Inc.'s innovative vaccine technology. Affinivax Inc., a US-based provider of vaccine technology, focuses on the development of malaria vaccines.
Major companies operating in the malaria vaccines market report are Pfizer Inc., Ipca Laboratories Ltd., Novartis AG, Sanofi SA, GlaxoSmithKline Plc., Takeda Pharmaceutical Co Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC., Lupin, Taj Pharmaceuticals Limited., Nobelpharma Co. Ltd., Bliss GVS Pharma Ltd., Sanaria Inc., Precigen Inc., AdvaCare Pharma, CellFree Sciences, Actiza Pharmaceutical Private Limited, Sumaya Biotech, VLP Therapeutics LLC, GeoVax Labs Inc., Zydus Cadila, Genvec Inc.
North America was the largest region in the malaria vaccines market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the malaria vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the malaria vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The malaria vaccines market consists of sales of circumsporozoite protein (CSP) antigens, multi-component adjuvants, and circumsporozoite protein. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Malaria Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on malaria vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for malaria vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The malaria vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Agent: Plasmodium Falciparum; Plasmodium Vivax; Anopheles Species
2) By Vaccine Type: Pre-Erythrocytic; Erythrocytic; Multi-antigen; Other Vaccines
3) By Route Of Administration: Intramuscular; Subcutaneous; Intradermal; Other Routes
4) By Distribution Channel: Public; Private
Subsegments:
1) By Plasmodium Falciparum: RTS,S/AS01 Vaccine; Other Experimental Vaccines
2) By Plasmodium Vivax: Candidate Vaccines In Development; Combination Vaccines
3) By Anopheles Species: Transmission-Blocking Vaccines; Vector Control Approaches
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Malaria Vaccines Market Characteristics
3. Malaria Vaccines Market Trends And Strategies
4. Malaria Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Malaria Vaccines Growth Analysis And Strategic Analysis Framework
5.1. Global Malaria Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Malaria Vaccines Market Growth Rate Analysis
5.4. Global Malaria Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Malaria Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Malaria Vaccines Total Addressable Market (TAM)
6. Malaria Vaccines Market Segmentation
6.1. Global Malaria Vaccines Market, Segmentation By Agent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasmodium Falciparum
Plasmodium Vivax
Anopheles Species
6.2. Global Malaria Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pre-Erythrocytic
Erythrocytic
Multi-antigen
Other Vaccines
6.3. Global Malaria Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intramuscular
Subcutaneous
Intradermal
Other Routes
6.4. Global Malaria Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Public
Private
6.5. Global Malaria Vaccines Market, Sub-Segmentation Of Plasmodium Falciparum, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RTS,S/AS01 Vaccine
Other Experimental Vaccines
6.6. Global Malaria Vaccines Market, Sub-Segmentation Of Plasmodium Vivax, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Candidate Vaccines In Development
Combination Vaccines
6.7. Global Malaria Vaccines Market, Sub-Segmentation Of Anopheles Species, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Transmission-Blocking Vaccines
Vector Control Approaches
7. Malaria Vaccines Market Regional And Country Analysis
7.1. Global Malaria Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Malaria Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
